Revive Therapeutics Ltd.

136 articles about Revive Therapeutics Ltd.

• Revive Therapeutics Announces Grant of Stock Options

  12/27/2019

  Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, announces a grant of incentive stock options to its newly-constituted Board of Directors, totalling 4.3 million at an exercise price of 7 cents, vesting immediately and all unexercised options expiring after 5 years

• Revive Therapeutics Provides Update on its Cannabis-based Pharmaceutical Initiatives

  12/19/2019

  Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to provide an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel therapies for unmet medical needs in large and rare disease markets.

• Revive Therapeutics Announces New Leadership Appointment and Board Change

  12/19/2019

  Revive Therapeutics Ltd., a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that all the resolutions put forward by the Company at its annual general meeting of shareholders held on December 18, 2019 were approved at the AGM.

• Revive Therapeutics Announces Results for the Three Months Ended September 30, 2019

  11/27/2019

  Revive Therapeutics Ltd., a specialty cannabis company focused on the research, development, and commercialization of novel cannabinoid-based products, announced its results for the three months ended September 30, 2019.

• Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2019

  10/24/2019

  The Audited Financial Statements and Management's Discussion and Analysis for the year ended June 30, 2019, may be viewed on SEDAR at www.sedar.com.

• Revive Therapeutics and Herman Holdings Enter Into Non-Binding Letter of Intent to Merge

  10/17/2019

  Final terms will be set out in a definitive agreement to be entered into by the parties.

• Revive Therapeutics Submits Cannabinoid Delivery Technology Findings Abstract for 29th International Conference on Polyphenols and the 9th Tannin Conference

  1/31/2018

  The conference will be held July 16th through July 20th in Madison, Wisconsin.

• Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

  1/30/2018

  The research will be overseen by Sanyal Biotechnology LLC (“SanyalBio”), the Company’s strategic research partner for liver diseases.

• Revive Therapeutics Announces Update on its Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis...

  1/4/2018

  Revive Therapeutics today announced an update on the Company's collaboration agreement with Chemi Pharmaceutical Inc. ("Chemi Pharma"), a Licensed Dealer for cannabis pursuant to the Controlled Drugs and Substances Act under Health Canada and its assistance with the decentralization of services enabled by blockchain technology to be integrated and utilized for the benefit of medical cannabis patients.

• Revive Therapeutics Enters into Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis and US FDA Approved Laboratory

  12/18/2017

  The Agreement with Chemi Pharma strengthens Revive's ambition in becoming a leader in the medical cannabis market.

• Revive Therapeutics Announces Update on Development of Datametrex Artificial Intelligence Component in Blockchain Enabled Patient-Focused Program for Medical Cannabis Sector

  12/4/2017

  Revive Therapeutics announced an update on the development of the Artificial Intelligence ("AI") component for Revive's proposed proprietary patient-focused program dedicated to the medical cannabis industry enabled by Blockchain technology.

• Revive Therapeutics Announces Results for the Three Months Ended September 30, 2017

  11/30/2017

  The unaudited condensed interim consolidated financial statements and related interim management's discussion and analysis for the three months ended September 30, 2017 may be viewed on SEDAR at www.sedar.com.

• Revive Therapeutics Announces Successful Final Results of Novel Cannabinoid Delivery Technology Unlocking Commercialization Opportunities in the Medical Cannabis and Pharmaceutical Sectors

  11/29/2017

  The Company is positioned to advance the development and commercialization of novel medical cannabis products and pharmaceutical cannabinoid therapies internally, with licensed medical cannabis producers, and pharmaceutical companies.

• Revive Therapeutics Appoints Blockchain Expert, Bernie Doyle, as Technical Advisor to Support Development of Medical Cannabis Patient-Focused Program Enabled by Blockchain and AI Technology

  11/21/2017

  Mr. Doyle is a thought leader in the field of blockchain and he is dedicated to being a leader in connecting and educating government, organizations, businesses and individuals about blockchain.

• Revive Therapeutics Engages NYU School of Medicine For Cystinuria Phase 2 Study

  12/21/2016

• Revive Therapeutics Names a New CEO and President

  7/6/2016